Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Multiple Myeloma Research Consortium has initiated a three-drug combination study of elotuzumab, a humanized anti-CS1 monoclonal IgG1 antibody administered intravenously, in combination with Revlimid, and dexamethasone for the treatment of multiple myeloma in patients who are experiencing a relapse.
Subscribe to our email newsletter
Emory University’s Winship Cancer Institute, Washington University, and St Vincent’s Comprehensive Cancer Center of Saint Vincent Catholic Medical Centers of New York will evaluate the maximum tolerated dose of elotuzumab in combination with label dosing of lenalidomide and dexamethasone. The multi-center, open-label, dose-escalation Phase Ib study will enroll up to 26 patients.
Sagar Lonial, principal investigator of the study said: “This three drug combination study is a pivotal study for patients with relapsed multiple myeloma as they may benefit from the synergistic effects of a new monoclonal antibody with two currently available drugs. We look forward to testing this promising new combination.”
Kathy Giusti, founder and CEO of The Multiple Myeloma Research Consortium (MMRC), said: “The MMRC is proud to advance this combination trial as it aligns with our commitment to expand our portfolio of treatment options for multiple myeloma patients – especially those that show the most potential in effectively treating patients who have suffered a relapse.”